Drugs / Muscadine Grape Skin Extract
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02583269 | Mar 2016 → Dec 2017 | metastatic malignant neoplasm | Wake Forest University Health Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Muscadine Grape Skin Extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02583269 ↗ |
| Known as | MGE | “Preclinical studies with muscadine grape extract (MGE) show antitumor activity and decreased systemic inflammation.” PMID 33867481 ↗ Jun 2021 |
| Route | Oral | “Patients receive muscadine grape skin extract orally (PO) twice daily (BID).” NCT02583269 ↗ |